About this trial
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, with over 12 million patients expected globally by 2040. The disease is currently diagnosed at the appearance of motor symptoms, but by then, over 60% of striatal dopaminergic neurons have already been destroyed. Prodromal symptoms such as idiopathic REM Sleep Behavior Disorder (iRBD), anosmia, mood disorders and constipation appear earlier and are listed as criteria for a prodromal PD diagnosis. Identifying early signs is critical to initiate neuroprotective treatments as early as possible. While pain is prevalent and highly disabling in early PD, no data are currently available on pain perception in iRBD patients, whose condition is of the main risk factor for PD development.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosed with iRBD confirmed by polysomnography;
No clinical diagnosis of Parkinson's disease or other diagnosis of neurodegenerative disease;
Ability to understand and complete study procedures and questionnaires;
Diagnosed with narcolepsy type 1;
Disqualifiers
Diagnosed Parkinson's Disease, dementia with Lewy bodies or multiple system atrophy;
Severe depression according to Diagnostic and Statistical Manual of Mental Disorders (DSM V);
Inability to complete study procedures or questionnaires.
Trial design
Parallel
Treatments tested in this trial
Thermo test pain
Other interventionPatients will undergo a pain test, also called a thermotest, which consists of determining pain thresholds using a thermometer applied to the hand.
Pain questionnaires
Other interventionPatients will complete various questionnaires about pain
No motors symptoms evaluations
Other interventionPatients will complete questionnaires
Treatment groups
Trial outcomes
Primary outcomes
Comparison of the intensity of chronic pain between patients with iRBD and a control group of patients
Measuring the Visual Analog Scale (VAS) between patients with iRBD without diagnosis of PD and a control group of patients diagnosed with narcolepsy type 1 who present RBD (Rapid eye movement sleep behavior disorder).
Secondary outcomes
Describe semiological characteristics of pain in RBD patients
Description of characteristics of pain
Compare the presence of chronic pain
Number of patients with chronic pain in both groups for at least 3 months.
Assessing Pain Characteristics
Score obtained on pain questionnaires
Assessment of thermal pain threshold and tolerance
Results of the quantitative sensory test (thermal thermotest) in both groups
Sponsors and contacts
Click on the lead sponsor to view all of their trials.